Correlation Between Protalix Biotherapeutics and Rigel Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Protalix Biotherapeutics and Rigel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protalix Biotherapeutics and Rigel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protalix Biotherapeutics and Rigel Pharmaceuticals, you can compare the effects of market volatilities on Protalix Biotherapeutics and Rigel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protalix Biotherapeutics with a short position of Rigel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protalix Biotherapeutics and Rigel Pharmaceuticals.
Diversification Opportunities for Protalix Biotherapeutics and Rigel Pharmaceuticals
0.8 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Protalix and Rigel is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Protalix Biotherapeutics and Rigel Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rigel Pharmaceuticals and Protalix Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protalix Biotherapeutics are associated (or correlated) with Rigel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rigel Pharmaceuticals has no effect on the direction of Protalix Biotherapeutics i.e., Protalix Biotherapeutics and Rigel Pharmaceuticals go up and down completely randomly.
Pair Corralation between Protalix Biotherapeutics and Rigel Pharmaceuticals
Considering the 90-day investment horizon Protalix Biotherapeutics is expected to generate 1.63 times less return on investment than Rigel Pharmaceuticals. But when comparing it to its historical volatility, Protalix Biotherapeutics is 1.7 times less risky than Rigel Pharmaceuticals. It trades about 0.32 of its potential returns per unit of risk. Rigel Pharmaceuticals is currently generating about 0.31 of returns per unit of risk over similar time horizon. If you would invest 1,452 in Rigel Pharmaceuticals on August 29, 2024 and sell it today you would earn a total of 1,218 from holding Rigel Pharmaceuticals or generate 83.88% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Protalix Biotherapeutics vs. Rigel Pharmaceuticals
Performance |
| Timeline |
| Protalix Biotherapeutics |
| Rigel Pharmaceuticals |
Protalix Biotherapeutics and Rigel Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Protalix Biotherapeutics and Rigel Pharmaceuticals
The main advantage of trading using opposite Protalix Biotherapeutics and Rigel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protalix Biotherapeutics position performs unexpectedly, Rigel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rigel Pharmaceuticals will offset losses from the drop in Rigel Pharmaceuticals' long position.| Protalix Biotherapeutics vs. Corvus Pharmaceuticals | Protalix Biotherapeutics vs. Aldeyra | Protalix Biotherapeutics vs. Checkpoint Therapeutics | Protalix Biotherapeutics vs. Cidara Therapeutics |
| Rigel Pharmaceuticals vs. Fortress Biotech | Rigel Pharmaceuticals vs. Reviva Pharmaceuticals Holdings | Rigel Pharmaceuticals vs. Pieris Pharmaceuticals | Rigel Pharmaceuticals vs. Cidara Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Complementary Tools
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |